EP Patent

EP2335690A1 — Mucoadhesive buccal tablets for the treatment of orofacial herpes

Assigned to Bioalliance Pharma SA · Expires 2011-06-22 · 15y expired

What this patent protects

The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention…

USPTO Abstract

The present invention relates to the treatment or prevention of mucocutaneous herpes simplex virus diseases using prolonged release mucoadhesive buccal tablets comprising an acyclic guanosine antiviral agent. These tablets are particularly suitable for the treatment or prevention of orofacial herpes.

Drugs covered by this patent

Patent Metadata

Patent number
EP2335690A1
Jurisdiction
EP
Classification
—
Expires
2011-06-22
Drug substance claim
No
Drug product claim
No
Assignee
Bioalliance Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.